OncoMatch/Clinical Trials/NCT04322617
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Is NCT04322617 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Anlotinib plus the same Immune Checkpoint Inhibitors. and Anlotinib plus the new Immune Checkpoint Inhibitors. for non-small cell lung cancer.
Treatment: Anlotinib plus the same Immune Checkpoint Inhibitors. · Anlotinib plus the new Immune Checkpoint Inhibitors. · Anlotinib — This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemo-immunotherapy — first line
Failed from first line Chemo-immunotherapy.
Cannot have received: EGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug.
Cannot have received: VEGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug.
Cannot have received: radiation therapy
Exception: Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.
Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity.
Lab requirements
Blood counts
Adequate bone marrow hematopoiesis
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04322617 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR antibody, VEGFR antibody, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages